Helius Medical Technologies Secures Key Reimbursement Approval
Helius Medical Technologies Achieves Significant Milestone
Recently, Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced a major breakthrough in healthcare reimbursement. The company, based in Newtown, Pa., received approval for the reimbursement of its Portable Neuromodulation Stimulator (PoNS®) device from a prominent healthcare provider. This approval marks an important step in improving patient access to advanced neurotechnology aimed at addressing balance and gait deficiencies.
Understanding the PoNS Device
The PoNS device represents a cutting-edge development in non-invasive treatments for neurologic conditions. By using a mouthpiece connected to a controller, it delivers neurostimulation, aiming to enhance physiological compensatory mechanisms within the brain. This approach is particularly focused on enhancing motor functions such as balance and gait.
The Importance of Reimbursement Approval
With this new reimbursement approval, the PoNS device has garnered a significant endorsement from the healthcare community. The reimbursement amount totals $18,100, which reflects the out-of-network pricing adjustments. This support from healthcare providers underscores the clinical efficacy of the PoNS device and its value in improving patient outcomes.
Expanding Accessibility to Patients
Dane Andreeff, President and CEO of Helius, expressed optimism regarding this development. He stated that the approval not only validates the clinical need for the PoNS device but also empowers the company to continue advocating for broader coverage options with commercial payors. Helius is committed to enhancing accessibility for patients suffering from conditions like multiple sclerosis (MS).
How the PoNS Therapy Works
PoNS therapy is designed to be used in conjunction with physical rehabilitation. The device applies mild electrical impulses to the tongue, which have been shown to effectively stimulate areas of the brain associated with movement and balance. It is indicated for individuals aged 22 years and older and is utilized as part of a comprehensive therapeutic exercise program.
Significant Clinical Evidence
Clinical studies have revealed that PoNS therapy can lead to substantial improvements in gait and balance. In stroke patients, notable reductions in the risk of falls have been documented, reinforcing the device's potential as a transformative therapeutic option in neurology. Furthermore, in Canada, the PoNS device is approved for various indications related to stroke and mild traumatic brain injury (mmTBI).
Helius's Future Growth Prospects
As Helius Medical Technologies continues its mission to improve lives through innovative neurotech solutions, the company is exploring additional strategies for expanding its market presence. This dedication to research and development aims at enhancing understanding and application of PoNS therapy, potentially leading to new therapeutic applications and improved patient care.
Investor Communication and Further Inquiries
To facilitate communication regarding the company's advancements and investor relations, Philip Trip Taylor from the Gilmartin Group is available for inquiries. Helius encourages interested parties to reach out for further information about the PoNS device or its ongoing initiatives. Their commitment to transparency and accessibility is evident in their dedication to stakeholder relations.
Frequently Asked Questions
What is the PoNS device used for?
The PoNS device is primarily used to improve balance and gait in patients with neurological conditions, specifically those dealing with multiple sclerosis and other related disorders.
How does the reimbursement for PoNS work?
Reimbursement for the PoNS device is approved at a total of $18,100, compensating patients while they undergo treatment that includes the device.
Is PoNS therapy effective?
Yes, clinical studies indicate that PoNS therapy is effective in improving balance and reducing fall risk, especially in patients recovering from strokes.
Who can use the PoNS device?
The PoNS device is indicated for adults aged 22 years and older and is prescribed as part of a structured therapy program.
How can I learn more about Helius Medical Technologies?
For more information about Helius Medical Technologies and the PoNS device, visit their official website at www.heliusmedical.com.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.